Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 67

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 67
---
 to develop or commercialize products or drug candidates unless we successfully pursue litigation to nullify
or invalidate the other IP rights concerned, or enter into a license agreement with the IP right holder, if available on commercially
reasonable terms.

If we are unable to obtain and maintain the appropriate scope for our patents, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and drugs may be adversely affected.

We may not obtain sufficient
claim scope in those patents to prevent another party from competing successfully with our drug and diagnostics technology candidates.
Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent
competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our
patents by developing similar or alternative technology or drug and diagnostics technology candidates in a non-infringing manner. The
issuance of a patent is not conclusive as to its scope, validity or enforceability, and our patents may be challenged in the courts or
patent offices in the United States and abroad. Such challenges may result in patent claims being narrowed, invalidated or held unenforceable,
which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology
and drug and diagnostics technology candidates, or limit the duration of the patent protection of our technology and drug and diagnostics
technology candidates. Given the amount of time required for the development, testing and regulatory review of new drug and diagnostics
technology candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As
a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing drug and diagnostics technology
candidates similar or identical to ours.

Further, the issuance, scope,
validity, enforceability and commercial value of our and our current or future licensors’ or collaboration partners’ patent
rights are highly uncertain. Our and our licensors’ pending and future patent applications may not result in patents being issued
which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies
and products.

We may not be able to protect and enforce our IP rights throughout the world.

Our commercial success will
depend, in part, on our ability to maintain IP protection for our drug candidates in which we seek to develop and commercialize. While
we rely primarily upon a combination of patents,